Palvella Therapeutics, Inc. Contract Liability (Deferred Revenue)
Palvella Therapeutics, Inc. (PVLA) had Contract Liability (Deferred Revenue) of $0 as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-03-29
- 2023-12-31: Contract with Customer, Liability, Current $0.00.
- 2023-09-30: Contract with Customer, Liability, Current $994.00K.
- 2023-06-30: Contract with Customer, Liability, Current $17.68M.
- 2023-03-31: Contract with Customer, Liability, Current $26.69M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | $994.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $17.68M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $26.69M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $20.82M 10-K · filed 2024-03-29 |
| 2022-09-30 | $18.50M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $22.86M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $20.91M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $25.12M 10-K · filed 2023-03-31 |
| 2021-09-30 | $26.45M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $25.54M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $17.24M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $12.63M 10-K · filed 2022-03-02 |
| 2020-09-30 | $10.04M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $7.91M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $10.04M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $11.26M 10-K · filed 2021-03-31 |
| 2019-09-30 | $27.24M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $28.41M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $28.18M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $35.61M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |